Vanessa Research (VR), a Hamden, Conn.-based biomedical company committed to improving patient quality of life by developing innovative solutions for unmet medical needs, proudly supported Rare Disease Day for the fourth consecutive year last week. Unlike years past, in 2021 events were virtual because of the ongoing global COVID-19 pandemic.
Rare Disease Day is observed internationally each year on the last day of February, because that day is viewed as the rarest day of the year. The aim of the day is to raise awareness regarding the 300 million people worldwide who are battling rare diseases.
A social media campaign kicked off the last week of February 2021 to help shine a light on rare disease worldwide, and to raise funds for rare disease research for two non-profits: the National Organization for Rare Disorders (NORD) in the United States and EURORDIS in Europe. The campaign included highlights from a global employee event that connected VR employees across all the VR campuses in the United States, Hungary, Spain, and Germany.
Additionally, to support the day’s objective, Dr. Dmitry Kravtsov, VP of Research and Development at VR, spoke at the Connecticut Rare Action Network Rare Disease Day Virtual Event Friday, Feb. 26, 2021 to educate Connecticut legislators and the public on the challenges faced by rare disease patients and their families. Dr. Kravtsov discussed the lethal Microvillus Inclusion Disease (MVID), a rare pediatric gastrointestinal disorder. VR currently has orphan drug designation through the European Medicine Agencies for Shylicine™ its candidate for treating MVID; Shylicine™ is currently in a Phase 2 clinical trial.
About Vanessa Research
Vanessa Research (VR) is a biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets that are often overlooked. The continually expanding pipeline of innovative pharmaceuticals, medical devices, and consumer and public health products reflects the company’s inventive nature and commitment to delivering solutions that increase access to quality care. The company’s flagship product, Shylicine™, is the first-ever drug developed to treat the rare, lethal microvillus inclusion disease.
VR, a University of Connecticut Technology Incubation Program participant, has global offices in Hungary, Spain and Germany in addition to its Hamden, Conn. corporate campus.
PO Box 185755 Hamden CT 06518 USA
+1 203 836 8424